By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Merrimack Pharmaceuticals Inc. 

101 Binney Street

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-441-1000 Fax: 617-491-1386


SEARCH JOBS



Segment
Start Up

Collaborations

Dyax Corp.  Antibody phage display





Company News
Merrimack Pharmaceuticals Inc. (MACK) Reports Second Quarter 2014 Financial Results 8/11/2014 7:41:11 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of HERMIONE, A Randomized Trial Of MM-302 In Patients With Advanced HER2-Positive Breast Cancer To Support Application For Accelerated Approval 8/11/2014 7:33:02 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Timing Of Second Quarter 2014 Investor Conference Call 8/4/2014 3:38:56 PM
Merrimack Pharmaceuticals Inc. (MACK) Presents Data From Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/26/2014 7:39:47 AM
Sanofi (France) (SAN.PA) Throws Cancer Drug Back To Merrimack Pharmaceuticals Inc. (MACK) 6/20/2014 6:57:26 AM
Merrimack Pharmaceuticals Inc. (MACK) Announces Oral Presentation Of Additional Data Results In Phase 3 NAPOLI-1 Study At The ESMO 16th World Congress On Gastrointestinal Cancer 6/17/2014 8:50:14 AM
Merrimack Pharmaceuticals Inc. (MACK) Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs At The 2014 American Society of Clinical Oncology Annual Meeting 6/2/2014 4:52:04 PM
Merrimack Pharmaceuticals Inc. (MACK) Identifies Heregulin As Patient Response Biomarker For MM-121 And Standard Of Care Therapy Across Multiple Cancers 6/2/2014 9:28:51 AM
Merrimack Pharmaceuticals Inc. (MACK) To Present At The Jefferies and Co. 2014 Global Healthcare Conference 5/27/2014 9:15:01 AM
Merrimack Pharmaceuticals Inc. (MACK) To Present Clinical Data Across Oncology Pipeline At American Society of Clinical Oncology 2014 5/23/2014 10:15:21 AM
12345678910...
//-->